Stocktoria
Voyager Acquisition Corp./Cayman Islands VACH
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-08-09
Voyager Acquisition Corp./Cayman Islands financials (annual, from 10-K)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| SG&A expense | $10,000 | $10,000 |
| Operating income | -$1.8M | -$702,959 |
| Net income | $9.0M | $4.1M |
| EPS (diluted) | — | $0.24 |
| Operating cash flow | -$486,182 | -$703,468 |
| Cash & equivalents | $133,831 | $668,285 |
| Total assets | $270.1M | $259.8M |
| Total liabilities | $13.3M | $12.1M |
| Shareholders' equity | -$13.1M | -$11.4M |
Growth · year-over-year
| Metric | FY2025 | FY2024 |
|---|---|---|
| Net income growth | +117.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0002006815 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.